Advertisement

Topics

PubMed Journals Articles About "Eylia Drug Insights 2017 Updated 30052017 Prices From" RSS

07:44 EST 20th January 2019 | BioPortfolio

Eylia Drug Insights 2017 Updated 30052017 Prices From PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Eylia Drug Insights 2017 Updated 30052017 Prices From articles that have been published worldwide.

More Information about "Eylia Drug Insights 2017 Updated 30052017 Prices From" on BioPortfolio

We have published hundreds of Eylia Drug Insights 2017 Updated 30052017 Prices From news stories on BioPortfolio along with dozens of Eylia Drug Insights 2017 Updated 30052017 Prices From Clinical Trials and PubMed Articles about Eylia Drug Insights 2017 Updated 30052017 Prices From for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eylia Drug Insights 2017 Updated 30052017 Prices From Companies in our database. You can also find out about relevant Eylia Drug Insights 2017 Updated 30052017 Prices From Drugs and Medications on this site too.

Showing "Eylia Drug Insights 2017 Updated 30052017 Prices from" PubMed Articles 1–25 of 16,000+

California's Drug Transparency Law: Navigating The Boundaries Of State Authority On Drug Pricing.

The California drug transparency bill (SB-17), signed into law in October 2017, seeks to promote transparency in pharmaceutical pricing, enhance understanding about pharmaceutical pricing trends, and assist in managing pharmaceutical costs. This article examines the legal and regulatory aspects of SB-17, explores legal challenges to the law, compares it to other state efforts to address rising drug prices, and discusses how California can maximize the impact of SB-17 by coupling the law with other incentiv...


DrugCentral 2018: an update.

DrugCentral is a drug information resource (http://drugcentral.org) open to the public since 2016 and previously described in the 2017 Nucleic Acids Research Database issue. Since the 2016 release, 103 new approved drugs were updated. The following new data sources have been included: Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), FDA Orange Book information, L1000 gene perturbation profile distance/similarity matrices and estimated protonation constants. New and existing entries...

Why drug prices will continue to roil the waters-and why Scott Gottlieb, MD, will be in the center of the action.

We'll see what happens to the administration's Part B proposal. Congress is not likely to take bold action, partly because drugmakers are a strong influence on both parties. That leaves the FDA and Administrator Scott Gottlieb, MD, as major players in efforts to rein in drug prices.


Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.

Both overall survival (OS) and progression-free survival (PFS) are primary endpoints of phase III studies of new anticancer drugs. Medical care expenditures, especially oncology drug prices, are rapidly increasing; however, impact of oncology drug prices on OS and PFS is unclear. We analyzed the relations between oncology drug prices and clinical outcomes in Japan. The costs of a full course or 1 year of treatment were estimated on the basis of the latest National Health Insurance Drug Price Standards, and ...

Linking resource supplies and price drivers: lessons from Traditional Chinese Medicine (TCM) price volatility and change, 2002 - 2017.

Worldwide, one of the drivers of substitution and adulteration is the cost of the natural resources (plants, animals, fungi) that are ingredients of traditional medicines. Relatively few studies have been done that link prices of traditional medicine ingredients to what drives changes in price, yet this is an important topic. Theoretically, prices have been widely considered as an economic indicator of resource scarcity. Rare, slow growing medicinal plants sell for high prices and common, less popular speci...

The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions.

As the name suggests, drug repurposing is a strategy to identify new therapeutic uses for marketed drugs, discontinued and/or shelved drugs, and drug candidates currently in clinical development. Although not a recent concept, drug repurposing has gained momentum over the past few years and several drugs have been successfully repurposed. Here, we summarize the drug repurposing landscape from 2012 to 2017, with a major focus on repurposed drugs, collaborative opportunities, and funding opportunities specifi...

Pharmaceutical Policy Reforms to Regulate Drug Prices in Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea.

Medicine price directly affects affordability and access to medicines particularly in countries where a major portion of pharmaceutical spending is through out-of-pocket payment, such as in the Asia Pacific region. We have undertaken a detailed appraisal of the pharmaceutical policy reforms to regulate drug prices in 3 developed (Australia, New Zealand, and South Korea) and 3 emerging (China, India, and Malaysia) economies of the Asia Pacific region. Despite continuous efforts by the authorities in adopting...

Generic Drug Price Hikes And Out-Of-Pocket Spending For Medicare Beneficiaries.

Recent increases in prices of longtime generic drugs have focused attention on competition in generic markets. We used Medicare Part D data for the period 2006-15 to examine sudden large price increases in generic drugs in the context of their base prices, duration, and accompanying changes in patients' out-of-pocket spending. The fraction of drugs that at least doubled in price increased from 1.00 percent of generic products in 2007 to 4.39 percent in 2013. Almost all were initially low- or medium-price ...

Prices For Cardiac Implant Devices May Be Up To Six Times Higher In The US Than In Some European Countries.

Medical devices are estimated to account for 6 percent of health expenditures in the US and 7 percent in European Union (EU) countries. Cardiac implants are a large segment of the market, but little is known about their prices. Using 2006-14 data from a large hospital panel survey, this article provides a systematic comparison of prices of cardiac implants between the US and four EU countries. The data reveal that prices were two to six times higher in the US than in Germany, where cardiac implants were g...

The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.

We investigated the South African tendering system for medicines to (a) evaluate its impact on prices and market concentration over a 14-year period and (b) analyze the accuracy of government forecasts of drug demand.

Prices for physician services in Medicare Advantage versus traditional Medicare.

To compare the prices paid to physicians by employer-sponsored Medicare Advantage (MA) plans with those paid by traditional Medicare (TM) and to determine whether the relationship between MA and TM prices is affected by the generosity of MA benchmarks.

Will Courts Allow States to Regulate Drug Prices?

How do housing prices affect consumption in China? New evidence from a continuous wavelet analysis.

In this paper, we revisit the relationship between housing prices and consumption in China by using a continuous wavelet analysis. This method provides an insight into the dynamic nexus in both time and frequency domains. In general, Empirical results show that there is a positive relationship between the two series in China, although it varies across time and frequencies. First, we find that disposable income is the core factor which affects both consumption and housing prices in China. Second, housing pri...

Social Determinants, Drug And Device Prices, And More.

Correction to: Reassessing Coronary Artery Bypass Surgery Versus Percutaneous Coronary Intervention in Patients with Type 2 Diabetes Mellitus: A Brief Updated Analytical Report (2015-2017).

In the original publication, conclusion was incorrectly updated in the article main text. The complete statement is given below.

Generic Drugs in the United States: Policies to Address Pricing and Competition.

The cost of prescription drugs in the U.S. continues to be a source of concern for patients, caregivers, and policymakers. Drug prices typically decline rapidly once generic drugs receive U.S. Food and Drug Administration (FDA) approval and enter the market, but the past decade has witnessed rising costs and shortages of generic drugs. We describe the strategies employed by brand-name manufacturers to undermine generic competition and the reasons underlying the price increases of off-patent drugs, some of w...

Disclosing Prescription-Drug Prices in Advertisements - Legal and Public Health Issues.

An Updated History of AAGL (2001 -2017).

Correction: Pharmacy Benefit Managers, Brand-Name Drug Prices, and Patient Cost Sharing.

Early Childhood Education Centers' Reported Readiness to Implement the Updated Child and Adult Care Food Program Meal Pattern Standards in the United States, 2017.

The Child and Adult Care Food Program (CACFP) serves nutritious meals/snacks to >3.6 million children in early childhood education (ECE) centers. This study provides a nationwide assessment of nonhome-based CACFP-participating ECE centers' awareness of and reported readiness for implementing updated CACFP standards/best practices that took effect October 1, 2017.

Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value.

Health care reimbursement agencies in countries other than the US often rely on cost-effectiveness evidence for drug coverage decisions, signaling to drug manufacturers their expectations for value-based pricing. To see whether drug prices in the US are influenced by value, we estimated the range of cost-effectiveness for thirty frequently prescribed cardiovascular drugs. We extrapolated evidence from randomized controlled trials to determine average lifetime quality-adjusted life-years (QALYs) and payer-re...

Comparing Two Classification Schemes for Seizures and Epilepsy in Rural China.

The International League Against Epilepsy (ILAE) updated the classifications of seizures and epilepsies in 2017. We compared the 2017 classifications with the 1980's classifications in rural China.

The "American (Cancer) Patients First" Plan to Reduce Drug Prices-A Critical Assessment.

Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.

Antihypertensive drugs are often used in the belief that lowering blood pressure will prevent progression to more severe disease, and thereby improve pregnancy outcome. This Cochrane Review is an updated review, first published in 2001 and subsequently updated in 2007 and 2014.

Corrigendum to 'Current state and challenges in developing oral vaccines' Adv. Drug Deliv. Rev. 114 (2017) 116-131.


Advertisement
Quick Search
Advertisement
Advertisement